• Explore /
  • Poster
  • / A phase 1/2 open-label, multicenter, dose escalation and expansion study of AVB-001, an intraperitoneally administered, cell-generated, human IL-2 immunotherapy in patients with platinum-resistant, high-grade, serous adenocarcinoma of the ovary, primary peritoneum, or fallopian tube.

A phase 1/2 open-label, multicenter, dose escalation and expansion study of AVB-001, an intraperitoneally administered, cell-generated, human IL-2 immunotherapy in patients with platinum-resistant, high-grade, serous adenocarcinoma of the ovary, primary peritoneum, or fallopian tube.

Abstract Poster

Authors

Shannon Westin

Shannon Neville Westin

University of Texas MD Anderson Cancer Center, Houston, TX

Shannon Neville Westin , Oladapo O. Yeku , Travis T. Sims , Amy Bregar , Karen Andreas , Eric Soliman , Manish Jain , Claudio Dansky Ullmann , Amir A. Jazaeri

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Ovarian Cancer

Clinical Trial Registration Number

NCT05538624

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr TPS5616)

DOI

10.1200/JCO.2023.41.16_suppl.TPS5616

Abstract #

TPS5616

Poster Bd #

309a

Abstract Disclosures

Similar Posters

First Author: Thomas J. Herzog

First Author: Thomas J. Herzog

First Author: Jennifer O'Neil

First Author: Rodabe Navroze Amaria